| 1. |
The Global Initiative for Chronic Obstructive Lung Disease. GOLD 2018: Global Strategy for the Diagnosis, Management and Prevention of COPD[EB/OL]. (2017-11-01)[2018-6-28]. Available at: https://goldcopd.org.
|
| 2. |
Wang C, Xu JY, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] Study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
|
| 3. |
Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 2000, 356(9240): 1480-1485.
|
| 4. |
Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol, 2014, 5: 570.
|
| 5. |
Hamad GA, Cheung W, Crooks MG, et al. Eosinophils in COPD: how many swallows make a summer?. Eur Respir J, 2018, 51(1): pii1702177.
|
| 6. |
Kolsum U, Damera G, Pham TH, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol, 2017, 140(4): 1181-1184.
|
| 7. |
Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med, 2017, 5(12): 956-967.
|
| 8. |
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med, 2011, 184(6): 662-671.
|
| 9. |
Pascoe S, Locantore N, Dransfeld MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015, 3(6): 435-442.
|
| 10. |
Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med, 2018, 6(2): 117-126.
|
| 11. |
Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease: The Copenhagen General Population Study. Am J Respir Crit Care Med, 2016, 193(9): 965-974.
|
| 12. |
Suissa S, Dell'Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med, 2018, 6(11): 855-862.
|
| 13. |
Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2018, 141(6): 2037-2047.
|
| 14. |
Cheng SL, Lin CH. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2341-2348.
|
| 15. |
Kerkhof M, Sonnappa S, Postma DS, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J, 2017, 50(1): pii1700761.
|
| 16. |
Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. Science, 2004, 305(5691): 1776-1779.
|
| 17. |
Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J, 2014, 44(6): 1697-1700.
|
| 18. |
Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J, 2016, 47(5): 1374-1382.
|
| 19. |
王曉晟, 李敏, 康筱玲, 等. 慢性阻塞性肺疾病患者肺功能分組的臨床特征和治療反應比較. 中華結核和呼吸雜志, 2015, 38(12): 901-906.
|
| 20. |
Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med, 2018, 378(18): 1671-1680.
|
| 21. |
Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 374(23): 2222-2234.
|
| 22. |
Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD: relationship with bacterial load. Respir Res, 2017, 18(1): 88.
|
| 23. |
Vedel-Krogh S, Nordestgaard BG, Lange P, et al. Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD. Eur Respir J, 2018, 51(5): pii1800120.
|
| 24. |
Pavord ID, Lettis S, Anzueto A, et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med, 2016, 4(9): 731-741.
|
| 25. |
傅晶, 米東輝, 靳蓉暉, 等. 血嗜酸性粒細胞在慢性阻塞性肺疾病急性加重期的臨床觀察. 中國實驗診斷學, 2018, 22(1): 61-63.
|
| 26. |
Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016, 4(5): 390-398.
|
| 27. |
Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J, 2017, 50(5): pii1701162.
|
| 28. |
Couillard S, Larivee P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest, 2017, 151(2): 366-373.
|
| 29. |
Prins HJ, Duijkers R, Lutter R, et al. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respir Med, 2017, 131: 118-124.
|
| 30. |
曾強林, 王曉明, 李珊娜, 等. 慢性阻塞性肺疾病急性加重患者血嗜酸粒細胞增高的發生情況及臨床特征. 中華醫學雜志, 2017, 97(40): 3166-3170.
|
| 31. |
Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalised exacerbations of COPD. Chest, 2016, 150(2): 320-328.
|
| 32. |
Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med, 2017, 377(17): 1613-1629.
|
1/5
WeChat